Sofosbuvir

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3717 publications

EXPRESS: Adherence and Sustained Virologic Response in HCV Treatment: A Real-World Comparison of Major Pangenotypic Direct-Acting Antivirals.

EXPRESS: Adherence and Sustained Virologic Response in HCV Treatment: A Real-World Comparison of Major Pangenotypic Direct-Acting Antivirals.

Journal: Journal of investigative medicine : the official publication of the American Federation for Clinical Research

Published: April 11, 2026

Antiviral treatment for chronic viral hepatitis B and C in children in Ostrava

Antiviral treatment for chronic viral hepatitis B and C in children in Ostrava

Journal: Klinicka mikrobiologie a infekcni lekarstvi

Published: February 24, 2026

Integrative multiomics dissection of LSM7 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma.

Integrative multiomics dissection of LSM7 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma.

Journal: Science progress

Published: January 19, 2026

Long-Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus-Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study.

Long-Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus-Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: January 16, 2026

Galactosylated bilosomes for liver-targeted delivery of ledipasvir: optimization, conjugate synthesis, and cellular evaluation.

Galactosylated bilosomes for liver-targeted delivery of ledipasvir: optimization, conjugate synthesis, and cellular evaluation.

Journal: Pharmaceutical development and technology

Published: January 06, 2026

Virological and antifibrotic efficacy of antiviral treatment for hepatitis В+C in HIV-positive patients.

Virological and antifibrotic efficacy of antiviral treatment for hepatitis В+C in HIV-positive patients.

Journal: Wiadomosci lekarskie (Warsaw, Poland : 1960)

Published: December 16, 2025

Real-world Effectiveness and Safety of Coblopasvir plus Sofosbuvir in the Treatment of Chronic Hepatitis C Infection in Wenzhou, Eastern China: A Multicenter Observational Study.

Real-world Effectiveness and Safety of Coblopasvir plus Sofosbuvir in the Treatment of Chronic Hepatitis C Infection in Wenzhou, Eastern China: A Multicenter Observational Study.

Journal: Journal of clinical and translational hepatology

Published: December 10, 2025

Predictive Value of Sustained Virologic Response at Week 4 in Patients with Hepatitis C Virus Infection Treated with Sofosbuvir/Velpatasvir.

Predictive Value of Sustained Virologic Response at Week 4 in Patients with Hepatitis C Virus Infection Treated with Sofosbuvir/Velpatasvir.

Journal: Viruses

Published: December 01, 2025

Hepatitis C virus microelimination program in hemodialysis patients: success of a multi-stakeholder partnership based on a national eradication strategy.

Hepatitis C virus microelimination program in hemodialysis patients: success of a multi-stakeholder partnership based on a national eradication strategy.

Journal: Medicina

Published: November 28, 2025

Evolution of late hepatitis C relapse among patients with previous sustained virological responses: An 18-year prospective study.

Evolution of late hepatitis C relapse among patients with previous sustained virological responses: An 18-year prospective study.

Journal: Journal of global antimicrobial resistance

Published: November 14, 2025

Micro-elimination of Hepatitis C virus (HCV) infection in the General Population Cohort in rural Uganda: Long-term follow-up to assess feasibility and outcomes of a screening and treatment intervention.

Micro-elimination of Hepatitis C virus (HCV) infection in the General Population Cohort in rural Uganda: Long-term follow-up to assess feasibility and outcomes of a screening and treatment intervention.

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Published: November 10, 2025

KLHDC4 serves as a novel prognostic biomarker and drives tumor progression via PI3K/AKT signaling in clear cell renal cell carcinoma.

KLHDC4 serves as a novel prognostic biomarker and drives tumor progression via PI3K/AKT signaling in clear cell renal cell carcinoma.

Journal: Scientific reports

Published: October 30, 2025

Showing 1-12 of 3,717

Last Updated: 04/28/2026